Viridian Therapeutics’ Lumvoa is accredited for treating each the power and energetic phases of thyroid eye illness. This drug will provide sufferers a substitute for Tepezza, an Amgen drug that had been the one accredited remedy for this inflammatory eye dysfunction.
The publish FDA Approves Viridian’s Thyroid Eye Illness Drug, Competitor to a Blockbuster Amgen Med appeared first on MedCity Information.